{
    "clinical_study": {
        "@rank": "168190", 
        "arm_group": [
            {
                "arm_group_label": "D \u2192 M \u2192 D+M", 
                "arm_group_type": "Experimental", 
                "description": "D : DA-1229 5mg qd, M : metformin 1000mg bid"
            }, 
            {
                "arm_group_label": "D \u2192 D+M \u2192 M", 
                "arm_group_type": "Experimental", 
                "description": "D : DA-1229 5mg qd, M : metformin 1000mg bid"
            }, 
            {
                "arm_group_label": "M \u2192 D \u2192 D+M", 
                "arm_group_type": "Experimental", 
                "description": "D : DA-1229 5mg qd, M : metformin 1000mg bid"
            }, 
            {
                "arm_group_label": "M \u2192 D+M \u2192 D", 
                "arm_group_type": "Experimental", 
                "description": "D : DA-1229 5mg qd, M : metformin 1000mg bid"
            }, 
            {
                "arm_group_label": "D+M \u2192 M \u2192 D", 
                "arm_group_type": "Experimental", 
                "description": "D : DA-1229 5mg qd, M : metformin 1000mg bid"
            }, 
            {
                "arm_group_label": "D+M \u2192 D \u2192 M", 
                "arm_group_type": "Experimental", 
                "description": "D : DA-1229 5mg qd, M : metformin 1000mg bid"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, open-label, multiple dosing, three-way crossover clinical trial to\n      investigate the pharmacokinetic/pharmacodynamic drug-drug interaction of DA-1229 5 mg and\n      Metformin IR 1000 mg after oral administration in healthy male volunteers."
        }, 
        "brief_title": "Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects", 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 20 to 45, healthy male subjects(at screening)\n\n          -  Body weight between 55kg - 90kg, BMI between 18.0 - 27.0\n\n          -  FPG 70-125mg/dL glucose level(at screening)\n\n          -  Subject who totally understand the progress of this clinical trials, make decision by\n             his free will, and signed a consent form to follow the progress.\n\n        Exclusion Criteria:\n\n          -  Subject who has past or present history of any diseases following below.(liver\n             including hepatitis virus carrier, kidney, Neurology, immunology, pulmonary,\n             endocrine, hematooncology, cardiology, mental disorder)\n\n          -  Subject who had GI tract disease(Crohn's disease, ulcer, acute or chronic\n             pancreatitis) or surgery(appendectomy, hernioplasty are excluded)\n\n          -  Subject who had drug(Aspirin, antibiotics) hypersensitivity reaction\n\n          -  Subject who already participated in other trials in 2 months\n\n          -  Subject who had whole blood donation in 2 months, or component blood donation in 1\n             months or transfusion in 1 months currently."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941199", 
            "org_study_id": "DA1229_DIM_I"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "D \u2192 M \u2192 D+M", 
                    "D \u2192 D+M \u2192 M", 
                    "M \u2192 D \u2192 D+M", 
                    "M \u2192 D+M \u2192 D", 
                    "D+M \u2192 M \u2192 D", 
                    "D+M \u2192 D \u2192 M"
                ], 
                "intervention_name": "DA-1229", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "D \u2192 M \u2192 D+M", 
                    "D \u2192 D+M \u2192 M", 
                    "M \u2192 D \u2192 D+M", 
                    "M \u2192 D+M \u2192 D", 
                    "D+M \u2192 M \u2192 D", 
                    "D+M \u2192 D \u2192 M"
                ], 
                "intervention_name": "metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "D \u2192 M \u2192 D+M", 
                    "D \u2192 D+M \u2192 M", 
                    "M \u2192 D \u2192 D+M", 
                    "M \u2192 D+M \u2192 D", 
                    "D+M \u2192 M \u2192 D", 
                    "D+M \u2192 D \u2192 M"
                ], 
                "intervention_name": "DA-1229 + metformin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Clinical Trial Center, Seoul National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 5 mg and Metformin IR 1000 mg After Oral Administration in Healthy Male Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC\u03c4,ss of DA-1229 and metformin", 
                "safety_issue": "No", 
                "time_frame": "up to 168h"
            }, 
            {
                "measure": "Cmax,ss of DA-1229 and metformin", 
                "safety_issue": "No", 
                "time_frame": "up to 168h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941199"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}